About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00150371

Canadians Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration

The objective of this study is to assess the effectiveness of an atorvastatin treatment regimen involving starting doses between 10 and 80 mg, followed by a single-step titration (except for subjects ...

Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.•84 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Age

30 - 79 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age 30 to 79 years old
•Triglyceride level 6.8 mmol/L at screening
•LDL-C of 5.7 mmol/L at screening

Exclusion Criteria

•Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception. The latter are defined as: abstinence, surgical sterilization, oral contraceptives for at least 3 cycles, intrauterine device, implant, depot injection, or barrier method in conjunction with contraceptive foam or jelly.
•Subjects whose blood cholesterol levels are controlled (LDL-C targets) with statins other than atorvastatin
•Subjects receiving 2 or more lipid lowering agents are excluded (statins + resins or fibrates or niacin or fish oils)

Related studies

RECRUITINGPhase 1

Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia

NCT06451770 · Hypercholesterolemia, Hypertriglyceridemia, and more

RECRUITINGPhase 3

IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

NCT07473960 · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia

Pharmacogenomic Informed Statin Prescribing

NCT06568601 · Hypercholesterolemia

Causes and Natural History of Dyslipidemias

NCT00353782 · Hypercholesterolemia, Atherosclerosis

RECRUITINGPhase 2

A Dose-exploration Study of EDP167 in HoFH

NCT07489209 · Homozygous Familial Hypercholesterolemia (HoFH)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 18, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment1,100

Start dateJun 2004

Last updatedFeb 18, 2021

Condition

Hypercholesterolemia

Locations shown

Pfizer Investigational Site

Calgary, Alberta

Pfizer Investigational Site

Calgary, Alberta

Pfizer Investigational Site

Calgary, Alberta

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 18, 2021Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions